POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.22.2021, 5:45pm CEST, WHO):   U.S. 74,227    India 15,786    Brazil 15,609    United Kingdom 51,484    Russia 37,141    Turkey 28,465    France 5,498    Iran 11,788    Argentina 1,218    Columbia 1,224    Italy 3,791    Germany 19,572    Mexico 5,069    Poland 5,716    Philippines 4,806    Ukraine 23,785    Malaysia 6,210    Peru 1,034    Netherlands 5,223    Iraq 1,882    Thailand 9,810    Czechia 3,638    Canada 2,641    Chile 1,793    Romania 15,410    Serbia 7,327    Kazakhstan 1,893    Cuba 1,435    Vietnam 3,636    Hungary 2,548    Austria 3,818    Greece 3,376    Georgia 4,155    Belarus 2,097    Bulgaria 4,816    Azerbaijan 2,005    Slovakia 3,470    Croatia 3,258    Ireland 2,026    Venezuela 1,254    Lithuania 3,016    Denmark 1,247    South Korea 1,440    Moldova 1,787    Slovenia 1,845    Armenia 2,146    Latvia 3,133    Estonia 1,323    China 51    Singapore 3,439    New Zealand 134    Australia 2,643   

Roche: COVID-19 self-test approved in Germany, antibody cocktail approved for treatment in Europe

Christian Fernsby |
Roche today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SARS-CoV-2 Rapid Antigen Test using a simple nasal swab for patient self-testing in Germany.

Article continues below




The test is a reliable rapid test for the qualitative detection of a specific SARS-CoV-2 antigen in nasal swab samples.

This rapid antigen test collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and more comfortable sampling procedure.

By following simple instructions, patients can perform the test at home with results ready after only 15 minutes. The test will be made available in pharmacies and requires no prescription.

Roche confirmed today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a scientific opinion supporting the use of the investigational antibody cocktail, casirivimab and imdevimab, as a treatment option for patients with confirmed COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19.

The CHMP’s scientific opinion provides a harmonised, EU-level opinion on the efficacy, quality and safety of casirivimab and imdevimab.

This review took place in parallel to the EMA’s ongoing rolling review process, which is used to speed up the formal marketing application assessment of a promising medicine during a public health emergency.

The CHMP assessed available data in patients with COVID-19, including data from the REGN-COV2 2067 trial, as well as supportive data from other settings.

Roche and Regeneron are collaborating to develop, manufacture and distribute casirivimab and imdevimab, to people around the globe, with the aim of having more than two million doses available in 2021.

Regeneron will be responsible for distributing the antibody cocktail in the US and Roche will be responsible for distribution outside the U.S., with the first Roche-manufactured doses already being distributed.

The investigational antibody cocktail of casirivimab and imdevimab continues to be evaluated in clinical trials in multiple settings for COVID-19: in non-hospitalised and certain hospitalised patients, including the open-label RECOVERY trial of hospitalised patients in the UK, and a trial for the prevention of COVID-19 in household contacts of infected individuals.

As of February 2021, approximately 23,000 people have participated in casirivimab and imdevimab clinical trials. Lower doses of casirivimab and imdevimab are also being studied with the aim of increasing the number of patients who could potentially be treated if the cocktail is approved.


What to read next

First HPV test for use with SurePath preservative fluid approved
More self-help books, more depression
Artery tests appear to function differently for women and men